Madrigal Pharmaceuticals (MDGL) Stock Forecast & Price Target

Madrigal Pharmaceuticals Inc. is demonstrating a strong positive outlook due to the impressive performance of its medication, Rezdiffra, which has shifted approximately two-thirds of patients with compensated cirrhotic primary hypertension (CSPH) to lower risk scores, showcasing its therapeutic efficacy. The company has also noted higher than expected real-world adherence and persistence rates, driven by the medication's health-related quality of life (HRQL) benefits, indicating robust demand and patient satisfaction. Furthermore, projections for Rezdiffra's market penetration and revenue potential have been significantly increased, with estimates reaching $7.1 billion by 2035, reflecting strong growth expectations as the company expands its patient base.

Madrigal Pharmaceuticals faces significant risks that contribute to a negative outlook, primarily stemming from the potential for lower than expected peak sales due to market competition and insufficient support from the medical community and payers. Additionally, the company's financial performance is expected to be adversely impacted in the first quarter of 2026 due to contracting dynamics, which could hinder revenue growth. Key risks include potential regulatory setbacks, clinical trial failures, delays in timelines, competitive threats in the MASH treatment landscape, and challenges in funding operations sustainably.